



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/660,122

09/11/2003

David J. Ecker

DIBIS-0002US.P3

7830

58057 7590 04/20/2007
MEDLEN & CARROLL LLP
101 HOWARD STREET
SUITE 350
SAN FRANCISCO, CA 94105

EXAMINER

FREDMAN, JEFFREY NORMAN

ART UNIT

PAPER NUMBER

1637

SHORTENED STATUTORY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE
--	-----------	---------------

3 MONTHS

04/20/2007

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

Office Action Summary

Application No.

10/660,122

Applicant(s)

ECKER ET AL.

Examiner

Jeffrey Fredman

Art Unit

1637

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 06 October 2006.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 30-34 and 50-55 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 30-34 and 50-55 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date <u>10/6/06</u> . | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on October 6, 2006 has been entered.

Status

2. Claims 30-34 and 50-55 are pending.

Claims 30-34 and 50-55 are rejected.

Any rejection which is not reiterated in this action is hereby withdrawn as no longer applicable.

Claim Rejections - 35 USC § 112

3. The rejection of claim 27 is moot in view of the cancellation of this claim.

Claim Rejections - 35 USC § 103

4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

5. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of

Art Unit: 1637

the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

6. Claims 30-34 and 50-54 are rejected under 35 U.S.C. 103(a) as being unpatentable over Jurinke et al (Genetic Analysis: Biomolecular Engineering (1996) 13:67-71) in view of Norder et al (J. Med. Virol. (1990) 31:215-221) and further in view of Koster (WO 98/20166).

Jurinke teaches a method of claims 23 and 30 of providing viral bioagent characterizing information (see abstract), comprising:

(a) amplifying nucleic acid from said virus with a pair of primers to conserved regions of a housekeeping gene that is conserved among members of a viral family to produce an amplification product (see page 68, where primers were selected in the highly conserved regions of the HBV genomes and where RT-PCR was performed on virus solutions),

wherein the amplification product corresponds to a bioagent identifying amplicon (see page 256, figure 1, where the amplification products are detected)

(b) measuring the molecular mass of said amplification product by mass spectrometry (see page 68, subheading "MALDI-TOF MS", where Jurinke measures the molecular mass with mass spectrometry).

(c) comparing the molecular mass of the amplification product with known molecular masses of known bioagent identifying amplicons of members of said viral family wherein a match of molecular mass of the amplification product with a known mass of a known bioagent identifying amplicon of a member of the viral family indicates the identity of the virus (see page 70, where the mass of sample 1 is compared to sample 3 to demonstrate the presence of HBV in the sample).

With regard to claims 25, 32, HBV are threat agents (see abstract) (also see page 36 of the specification which lists Hepatitis viruses as biological warfare threat agents).

With regard to claims 26, 33, Jurinke suggests detection of different subtypes (see page 71, column 1, "determining different HBV subtypes by different masses of the HBV related PCR products").

With regard to claims 48 and 54, Jurinke teaches detection of the HBV core antigen (see page 69, column 1, paragraph 2).

With regard to claims 45-47 and 51-53, Jurinke expressly suggests detection of HIV and HCV, where HCV is a member of the Flaviviridae family (see page 67, column 1).

Jurinke suggests analysis of subtypes but does not exemplify detection of four members of the HBV viral family. Jurinke suggests analysis in view of Norder do not teach analysis of respiratory pathogens.

Norder teaches typing of 8 subtypes of HBV by PCR (see page 219, figure 2, for example).

With regard to claim 24, Norder expressly teaches measuring with multiple pairs of primers (see figure 2 and page 216, column 2, for example).

Koster expressly teaches analysis of respiratory pathogens such as rhinovirus (see page 74, line 1) as well as influenza virus (see page 74, line 8). Koster also teaches analysis of HIV and HCV (see page 73, line 21 and page 74, line 21). Koster also teaches comparison of base compositions with both modified and unmodified products (see page 66, for example, as well as page 105, table II and pages 69-70). At page 105, table II, Koster provides the base composition of three different PCR products determined by MALDI-TOF. Koster provides the number of C, T, A, G and analog residues as shown in Table II at page 105. In particular, Koster expressly teaches the use of MALDI-TOF for diagnosis of bacterial or viral infections (see pages 73-79). Koster exemplifies this analysis in Example 5.

It would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made to detect multiple subtypes of HBV with mass spectrometry using the Jurinke method since Jurinke expressly teaches "Of interest is also the possibility of determining different HBV subtypes by different masses of the HBV related PCR products (see page 71, column 1)." Norder also expressly motivates subtype detection noting "It is anticipated that PCR technology, including sequencing of

Art Unit: 1637

amplified fragments, will provide a powerful tool for studying the molecular epidemiology of HBV (see page 220, column 2)." An ordinary practitioner would have been directly motivated by Jurinke to look at different HBV subtypes, including all eight subtypes recognized by Norder, based on the express motivation stated by Jurinke and based upon Norder's express motivation that subtype analysis would permit analysis of the epidemiology of HBV and Norder later notes, may also provide information on HIV transmission (see page 220, column 2).

Further, it would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made to utilize the viral targets and mass spectrometry method of Koster in the analytical method of Jurinke in view of Norder since Koster states "In another embodiment, an accurate sequence determination of a relatively large target nucleic acid, can be obtained by generating specifically terminated fragments from the target nucleic acid, determining the mass of each fragment by mass spectrometry and ordering the fragments to determine the sequence of the larger target nucleic acid (see page 75, line 26 to page 76, line 2)." So an ordinary practitioner would have been motivated to detect the PCR products of Jurinke in view of Norder with the base composition Mass spectrometric approach of Koster since Koster teaches that Mass Spectrometry is accurate and can improve the speed, mass accuracy and precision of the analysis (see abstract, for example).

7. Claim 55 is rejected under 35 U.S.C. 103(a) as being unpatentable over Jurinke et al (Genetic Analysis: Biomolecular Engineering (1996) 13:67-71) in view of Norder et

Art Unit: 1637

al (J. Med. Virol. (1990) 31:215-221) and further in view of Koster (WO 98/20166) and further in view of Vanderhallen et al (J. Clin. Microbiol. (1998) 36(12):3463-3467).

Jurinke in view of Norder and further in view of Koster teach the limitations of claims 30-34 and 51-54 as discussed above. Jurinke suggests analysis in view of Norder do not teach analysis of polymerase genes.

Vanderhallen teaches analysis of a polymerase gene for typing EMCV (see abstract).

It would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made to use the mass spectrometric approach of Jurinke in view of Norder and further in view of Koster to type EMCV since Jurinke notes "The detection strategy introduced here has a high potential for automation and represents a fast and reliable method of detection for HBV DNA in serum without the need for time consuming gel electrophoresis and labeling or hybridization procedures (see abstract)." Further, Vanderhallen motivates analysis of the EMCV polymerase noting "The PCR technique has increased the sensitivity of detection of viral nucleic acids in clinical specimens (see page 3465, column 2)." An ordinary practitioner, interested in improving sensitivity of EMCV detection, would have been motivated to combine the PCR method of Vanderhallen with the mass spectrometric analysis of Jurinke in view of Norder and further in view of Koster, in order to identify specific subtypes of viruses that are of clinical significance and permit epidemiological tracking of these viruses as taught by Norder.

Response to Amendment

8. The Declaration under 37 CFR 1.132 filed October 6, 2006 is insufficient to overcome the rejection of the claims based upon 35 U.S.C. 103 as set forth in the last Office action because:

The Declaration, which is the same declaration that has been persuasive in several other related cases, is not persuasive in this case because the skepticism evinced in the declaration is drawn to a requirement for broad range priming (see point 2 on page 2 of the declaration, "To my knowledge, no one ever previously proposed or disclosed combining broad range priming of nucleic acid of bioagents") to perform a comparison with a database of targets (see exhibit B, which discusses both Broad range priming as "TIGER's power comes from the use of broad range primers" and "a phylogenetic tree of relatedness can be constructed"). The importance of the database is exemplified in exhibit 3, which notes that the masses "can be correlated with a database that contains information about RNA weights for a given pathogen".

In the parent and related applications which have been allowed, both of these elements referred to in the Declaration have been present. In U.S. Patent 7,108,974 based upon application 10/156,608, claim 1 requires both primers which flank a variable sequence and a database of 19 or more molecular masses. Similarly, in 10/660,996 and 10/660,997, the claims require primers which flank a variable sequence and a comparison to a database of 19 or more molecular masses.

The current claims lack both requirements that were identified by the Declaration as being responsible for the success and the skepticism of the JASON group and which

appear in the exhibits. The claim does not require that the primers flank a variable region and there is no requirement for comparison with a database of sequences. Therefore, the declaration is not persuasive since the claim is not commensurate in scope with the declaration.

Response to Arguments

9. Applicant's arguments filed October 6, 2006 have been fully considered but they are not persuasive.\

Applicant argues that Jurinke in view of Norder do not teach primers which flank variable regions. In fact, this is not a required element of the claims. As discussed above, this is one of the two elements which in related cases rendered the claims allowable. However, the current claim 30 has no requirement for variable regions between the conserved regions. Even if it did, Norder teaches the use of conserved and variable regions in HBV for distinguishing subtypes (see page 216, column 2 "Highly conserved regions of the X and S genes, and also variable regions within the S gene utilizing reported differences between the d/y and w/r HBV genomes were chose for primer directed amplification").

Applicant argues that Koster does not remedy the need to detect sequences that are unknown. No such requirement is found in the claim.

Applicant the relies upon overcoming the previous rejections to overcome the remaining rejection with Vanderhallen. Since the initial rejections are maintained, so is the rejection over Vanderhallen.

Conclusion

10. While MPEP 706.07(b) notes that a final rejection is not proper when material was denied entry, that is not the current case. That is, the advisory denied entry to the amendment due to the presence of the "four or more members" limitation exclusively (see note in Advisory action). That limitation was not presented in the current claims, which simply incorporated the base composition analysis already addressed by the rejection utilizing the Koster reference. Therefore, it is proper to make the current action final on first action since the limitation which was denied entry is not in the claims and since the claims would have been properly finally rejected.

11. All claims are drawn to the same invention claimed in the application prior to the entry of the submission under 37 CFR 1.114 and could have been finally rejected on the grounds and art of record in the next Office action if they had been entered in the application prior to entry under 37 CFR 1.114. Accordingly, **THIS ACTION IS MADE FINAL** even though it is a first action after the filing of a request for continued examination and the submission under 37 CFR 1.114. See MPEP § 706.07(b). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of


Art Unit: 1637

the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jeffrey Fredman whose telephone number is (571)272-0742. The examiner can normally be reached on 6:30-3:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on (571)272-0782. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.


Jeffrey Fredman
Primary Examiner
Art Unit 1637
